KITE PHARMA, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2009-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.kitepharma.com
Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2018-10-12
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 15
- Registration Number
- NCT03704298
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Study to Evaluate the Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in People With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
- First Posted Date
- 2018-08-09
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 16
- Registration Number
- NCT03624036
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇮🇹IRCCS Ospedale San Raffaele, Milano, Italy
🇺🇸Emory University, Atlanta, Georgia, United States
Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2018-01-05
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 359
- Registration Number
- NCT03391466
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States
Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2017-10-24
- Last Posted Date
- 2023-10-19
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 17
- Registration Number
- NCT03318861
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸David Geffen School of Medicine at UCLA, Los Angeles, California, United States
Axicabtagene Ciloleucel Expanded Access Study
- First Posted Date
- 2017-05-15
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- Kite, A Gilead Company
- Registration Number
- NCT03153462
- Locations
- 🇺🇸
H. Lee Moffitt Cancer and Research Institute, Tampa, Florida, United States
🇺🇸University of Miami Hospital and Clinics, Miami, Florida, United States
🇺🇸The University of Kansas Hospital Investigational Drug Services, Westwood, Kansas, United States
Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers
- Conditions
- Interventions
- First Posted Date
- 2017-05-03
- Last Posted Date
- 2023-08-25
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 16
- Registration Number
- NCT03139370
- Locations
- 🇺🇸
Baylor Scott & White Charles A. Sammons Cancer Center, Dallas, Texas, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2017-04-07
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 159
- Registration Number
- NCT03105336
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
- Conditions
- Interventions
- First Posted Date
- 2016-10-06
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 37
- Registration Number
- NCT02926833
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Stanford Cancer Center, Palo Alto, California, United States
🇺🇸H Lee Moffitt Cancer Center, Tampa, Florida, United States
Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2015-12-09
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 95
- Registration Number
- NCT02625480
- Locations
- 🇺🇸
Ann & Robert H. Lurie Children's Hospital, Chicago, Illinois, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸University of Miami Hospital & Clinics, Miami, Florida, United States
A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)
- Conditions
- Interventions
- First Posted Date
- 2015-11-25
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 125
- Registration Number
- NCT02614066
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of MD Greenbaum Comprehensive Cancer Center, Baltimore, Maryland, United States